Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRXGet Rating) in a research note released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group upgraded Agile Therapeutics from a hold rating to a buy rating in a report on Tuesday, July 26th.

Agile Therapeutics Stock Down 3.4 %

Agile Therapeutics stock opened at $0.60 on Wednesday. The business’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $6.62. The stock has a market cap of $2.71 million, a price-to-earnings ratio of -0.02 and a beta of 1.22. Agile Therapeutics has a 12-month low of $0.49 and a 12-month high of $50.40.

Agile Therapeutics (NASDAQ:AGRXGet Rating) last issued its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) earnings per share (EPS) for the quarter. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. The company had revenue of $1.76 million for the quarter. As a group, sell-side analysts expect that Agile Therapeutics will post -2.19 EPS for the current year.

Institutional Investors Weigh In On Agile Therapeutics

Hedge funds have recently modified their holdings of the business. First Citizens Bank & Trust Co. acquired a new stake in shares of Agile Therapeutics during the first quarter worth about $42,000. Renaissance Technologies LLC raised its position in shares of Agile Therapeutics by 281.3% during the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 458,300 shares during the period. BlackRock Inc. raised its position in shares of Agile Therapeutics by 1.1% during the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company’s stock worth $319,000 after purchasing an additional 16,104 shares during the period. GSA Capital Partners LLP raised its position in shares of Agile Therapeutics by 25.1% during the fourth quarter. GSA Capital Partners LLP now owns 733,685 shares of the specialty pharmaceutical company’s stock worth $358,000 after purchasing an additional 147,194 shares during the period. Finally, Perceptive Advisors LLC raised its position in shares of Agile Therapeutics by 33.8% during the fourth quarter. Perceptive Advisors LLC now owns 21,294,485 shares of the specialty pharmaceutical company’s stock worth $10,394,000 after purchasing an additional 5,374,560 shares during the period. Institutional investors and hedge funds own 27.96% of the company’s stock.

About Agile Therapeutics

(Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Featured Stories

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.